# New release of the IXI™ platform and advanced biomarker partnerships

19 Nov 26

news

# New release of the IXI™ platform and advanced biomarker partnerships

Rebecca White

[  ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/news/new-release-of-the-ixi-platform-and-advanced-biomarker-partnerships/) [  ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/news/new-release-of-the-ixi-platform-and-advanced-biomarker-partnerships/) [  ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/news/new-release-of-the-ixi-platform-and-advanced-biomarker-partnerships/) [  ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/news/new-release-of-the-ixi-platform-and-advanced-biomarker-partnerships/) <a class="trigger-share-window d-md-none">  </a>

![IXI 10.9 updates](/assets/blog-images/IXI-10__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.9-updates.webp)**IXI™ enhances platform scale and clinical trial operational efficiency to support IXICO’s TechBio strategy in neurological diseases**

**New collaborations will add additional capabilities to the IXI™ product and service offering**

IXICO, a global leader in neuroscience imaging,  biomarker analytics and diagnostics, today announced the latest release of IXI™, the Company’s proprietary AI-powered platform that enables the management, processing and advanced analysis of brain imaging data to support clinical decision-making and accelerate the development of new treatments for neurological diseases.

In addition, IXICO has announced technology collaborations with Neuropacs Corp and ZRO Imaging to expand the capabilities of IXI™ in Parkinson’s disease and PET imaging respectively.

#### Latest IXI™ Release 

The latest IXI™ release incorporates a significant programme of underlying technology development that advances Platform infrastructure, design and user-experience (UX) to deliver greater clinical trial operational efficiency and image quality control.  Work has also been conducted to extend the scalability of IXI™ for external commercial use, wider adoption and integration. In doing so, IXICO is delivering on its roadmap to serve new commercial opportunities through technology licensing, integration and strategic partnerships.

#### IXI™ Collaborations  

IXICO has agreed two new technology collaborations with Neuropacs Corp and ZRO Imaging as part of its strategy to transform IXI™ into a comprehensive, one-stop marketplace for advanced neurological imaging biomarkers.

Complementing IXICO’s proprietary biomarker technology, Neuropacs Corp brings its De Novo authorised neuropacs™ FDA validated AIDP algorithm for Parkinson’s disease differentiation, while ZRO Imaging expands the Group’s PET imaging capabilities through advanced PET imaging methodologies and quantitative analysis tools for Alzheimer’s disease and other neurodegenerative disorders.

These collaborations enable IXICO to offer a broader range of cutting-edge third-party technologies through a single, integrated platform, simplifying customer access to advanced biomarker analysis tools and strengthening IXICO’s position as a technology partner to the neuroscience drug development industry.

Mark Austin, Chief Technology Officer of IXICO, commented: “This latest release represents another important step in the evolution of IXI™ and the delivery of our TechBio strategy. By making the platform more scalable and easier to integrate with external technologies, we are improving the efficiency of our core iCRO services while creating new opportunities to generate recurring revenues through technology licensing and partnerships. The recognition last week at the Citeline Biotech Awards 2026, winning Technology Innovation of the Year, provides powerful independent validation of the innovation and capabilities underpinning IXI™ and its potential to transform neurological imaging in clinical trials.

We are also delighted to collaborate with Neuropacs Corp and ZRO Imaging, whose technology  expands the range of advanced imaging biomarkers we can offer customers.

Together, these developments bring us closer to our ambition of creating a one-stop platform and leading technology destination, enabling customers to access more capabilities through IXICO while expanding our addressable market and creating opportunities for growth.”

[ Back to News  ](/news-and-resources/news/)

### Recents

![IXICO develops a new AI tool supporting radiologists to detect vascular dysfunction in Alzheimer’s disease](/assets/blog-images/Vascular-dysfunction-AI-tool__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp)

17 Nov 26

news

[IXICO develops a new AI tool supporting radiologists to detect vascular dysfunction in Alzheimer’s disease](/news-and-resources/news/new-ai-tool-supporting-radiologists-to-detect-vascular-dysfunction-in-alzheimers-disease/)

[IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/news-and-resources/news/2-7-million-phase-3-contract-win-in-huntingtons-disease/)

[IXICO presents research on novel methods to reduce unwanted variability in Huntington’s disease biomarker data ](/news-and-resources/news/ixico-presents-research-on-novel-methods-to-reduce-unwanted-variability-in-huntingtons-disease-biomarker-data/)

[IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/)

[IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/)

### Library

[November 2026](/news-and-resources/news/archive/2026/11/)

[October 2026](/news-and-resources/news/archive/2026/10/)

[September 2026](/news-and-resources/news/archive/2026/09/)

[July 2026](/news-and-resources/news/archive/2026/07/)

[June 2026](/news-and-resources/news/archive/2026/06/)

[May 2026](/news-and-resources/news/archive/2026/05/)

[April 2026](/news-and-resources/news/archive/2026/04/)

[March 2026](/news-and-resources/news/archive/2026/03/)

[February 2026](/news-and-resources/news/archive/2026/02/)

[January 2026](/news-and-resources/news/archive/2026/01/)

[2025](/news-and-resources/news/archive/2025/)

[2024](/news-and-resources/news/archive/2024/)

[2023](/news-and-resources/news/archive/2023/)

[2022](/news-and-resources/news/archive/2022/)

[2021](/news-and-resources/news/archive/2021/)

[2020](/news-and-resources/news/archive/2020/)

[2019](/news-and-resources/news/archive/2019/)
